InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

CompletedLast updated: 2 February 2024

This phase I trial is trying to determine how safe and tolerable a new intravenous drug (RO7296682) is in treating patients with advanced solid cancers (excluding some types of blood cancer)An Open-label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, PK (Pharmacokinetics)/PD (Pharmacodynamics) of RO7296682, a T-regulatory Cell Depleting Antibody in Participants With Advanced and/or Metastatic Solid Tumors

Clinical summary

Summary

This trial is divided into a dose-escalation (Part A) and dose-expansion (Part B) stage. Eligible patients enrolled in Part A will receive ascending doses of RO7296682 intravenously every three weeks until a maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) is defined. Part B of the study will commence once the MTD/RP2D has been defined. Eligible patients enrolled in this part of the study will receive a fixed dose of RO7296682 at the MTD/RP2D established.

Conditions

This trial is treating patients with advanced solid cancers (excluding some blood cancers).

Cancer

Multi-Cancer Multi-Cancer

Age

People18+

Phase

I

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Hoffmann-La Roche

Scientific Title

An Open-label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, PK (Pharmacokinetics)/PD (Pharmacodynamics) of RO7296682, a T-regulatory Cell Depleting Antibody in Participants With Advanced and/or Metastatic Solid Tumors

Eligibility

Inclusion

  1. Diagnosis of advanced and/or metastatic solid tumors who have progressed on all standard therapies, are intolerant to Standard-Of-Care (SOC), and/or are non-amenable to SOC. Participants whose tumors have known sensitizing mutation must have experienced disease progression (during or after treatment) or intolerance to treatment with a respective targeted therapy.
  2. Measurable disease according to RECIST v1.1.
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  4. Able to provide the most recent archival tumor tissue samples.
  5. Adequate cardiovascular, haematological, liver and renal function.
  6. Participants on therapeutic anticoagulation must be on a stable anticoagulant regimen.
  7. Women of Childbearing Potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods.
  8. Men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods and refrain from donating sperm.

Exclusion

  1. Pregnancy, lactation, or breastfeeding.
  2. Known hypersensitivity to any of the components of RO7296682, including but not limited to hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies.
  3. History or clinical evidence of central nervous system (CNS) primary tumors or metastases.
  4. Participants with another invasive malignancy in the last two years.
  5. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results.
  6. Participants with known active or uncontrolled infection.
  7. Positive HIV test at screening.
  8. Positive for Hepatitis B and C.
  9. Vaccination with live vaccines within 28 days prior to C1D1.
  10. Major surgical procedure or significant traumatic injury within 28 days prior to first RO7296682 infusion.
  11. Participants with wound healing complications.
  12. Dementia or altered mental status that would prohibit informed consent.
  13. History of Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS (drug rash with eosinophilia and systemic symptoms).
  14. Active or history of autoimmune disease or immune deficiency.
  15. Prior treatment with CPIs (e.g. anti-CTLA4, anti-PD1, anti-PDL1), immunomodulatory monoclonal antibodies (mAbs) and/or mAb-derived therapies (approved or investigational) is approved.
  16. Prior treatment with a CC chemokine receptor 4 (CCR4)-targeting (e.g. mogamulizumab) or a CD25-targeting agent (e.g. basiliximab) is prohibited.
  17. Treatment with standard radiotherapy, any chemotherapeutic agent, targeted therapy or treatment with any other investigational drug (defined as treatment for which there is currently no regulatory authority-approved indication) within 28 days or 5 half-lives of the drug (whichever is shorter), prior to the first RO7296882 administration on C1D1.
  18. Radiotherapy within the last 4 weeks before start of study drug treatment, with the exception of limited palliative radiotherapy (for which no wash out period is required).

Inclusion

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

Completed hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.